tiprankstipranks
Trending News
More News >
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
US Market
Advertisement

Inhibikase Therapeutics (IKT) Technical Analysis

Compare
166 Followers

Technical Sentiment

Overall Consensus
Sell
5Bullish
5Neutral
11Bearish
Technical Analysis Consensus
Buy
3Bullish
5Neutral
1Bearish
Moving Average Consensus
Strong Sell
2Bullish
0Neutral
10Bearish
Inhibikase Therapeutics’s (IKT) Moving Averages Convergence Divergence (MACD) indicator is -0.03, suggesting Inhibikase Therapeutics is a Buy.
Inhibikase Therapeutics’s (IKT) 20-Day exponential moving average is 1.71, while Inhibikase Therapeutics’s (IKT) share price is $1.68, making it a Sell.
Inhibikase Therapeutics’s (IKT) 50-Day exponential moving average is 1.76, while Inhibikase Therapeutics’s (IKT) share price is $1.68, making it a Sell.

Inhibikase Therapeutics (IKT) Pivot Points

Sep 14, 2025, 02:56 AM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
1.38
1.45
1.50
1.57
1.61
1.69
1.73
Fibonacci
1.45
1.50
1.52
1.57
1.61
1.64
1.69
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

Inhibikase Therapeutics (IKT) Moving Averages

Sep 14, 2025, 02:56 AM
Period
Simple
Exponential
MA5
1.64Buy
1.65Buy
MA10
1.71Sell
1.68Sell
MA20
1.73Sell
1.71Sell
MA50
1.76Sell
1.76Sell
MA100
1.87Sell
1.86Sell
MA200
2.22Sell
2.06Sell
Inhibikase Therapeutics’s (IKT) 10-Day exponential moving average is 1.68, while Inhibikase Therapeutics’s (IKT) share price is $1.68, making it a Sell.
Inhibikase Therapeutics’s (IKT) 100-Day exponential moving average is 1.86, while Inhibikase Therapeutics’s (IKT) share price is $1.68, making it a Sell.
Inhibikase Therapeutics’s (IKT) stock price is $1.68 and Inhibikase Therapeutics’s (IKT) 50-day simple moving average is 1.76, creating a Sell signal.
Inhibikase Therapeutics’s (IKT) stock price is $1.68 and Inhibikase Therapeutics’s (IKT) 100-day simple moving average is 1.87, creating a Sell signal.
Inhibikase Therapeutics’s (IKT) stock price is $1.68 and Inhibikase Therapeutics’s (IKT) 200-day simple moving average is 2.22, creating a Sell signal.

Inhibikase Therapeutics (IKT) Technical Indicators

Sep 14, 2025, 02:56 AM
Name
Value
Implied Action
RSI (14)
47.84
Neutral
STOCH (9,6)
27.04
Neutral
STOCHRSI (14)
27.12
Neutral
MACD (12,26)
-0.03
Buy
ADX (14)
9.16
Buy
Williams %R
-55.00
Buy
CCI (14)
-97.63
Neutral
ATR (14)
0.13
-
Ultimate Oscillator
48.57
Neutral
ROC
0.00
Sell
Inhibikase Therapeutics’s (IKT) Relative Strength Index (RSI) is 47.84, creating a Neutral signal.
Inhibikase Therapeutics’s (IKT) Trend Strength Indicator (ADX) is 9.16, creating a Buy signal.
Inhibikase Therapeutics’s (IKT) Commodity Channel Index (CCI) is -97.63, creating a Neutral signal.

FAQ

Is IKT a Buy, Hold, or Sell?
Based on IKT’s technical indicators, IKT is a Sell.
    What is IKT’s RSI (14)?
    IKT’s RSI (14) is 47.84, which suggests IKT is a Neutral.
      What is IKT’s MACD?
      IKT’s MACD is -0.03, which suggests IKT is a Buy.
        What is IKT’s 5-day moving average?
        IKT’s 5-day moving average is 1.64, which suggests IKT is a Buy.
          What is IKT’s 20-day moving average?
          IKT 20-day moving average is 1.73, which suggests IKT is a Sell.
            What is IKT’s 50-day moving average?
            IKT’s 50-day moving average is 1.76, which suggests IKT is a Sell.
              What is IKT’s 200-day moving average?
              IKT’s 200-day moving average is 2.22, which suggests IKT is a Sell.
                What is IKT’s Williams % R (14)?
                IKT’s Williams % R (14) is -55.00, which suggests IKT is a Buy.
                  What is IKT’s CCI (14)?
                  IKT’s CCI (14) is -97.63, which suggests IKT is a Neutral.
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis